SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe (SPIRIT V)
SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions
Sponsor: Abbott Medical Devices
Listed as NCT00402272, this PHASE4 trial focuses on Coronary Artery Disease and Coronary Disease and remains completed. Sponsored by Abbott Medical Devices, it has been updated 8 times since 2006, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Medical Devices
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India , Alkmaar, Netherlands , Arezzo, Italy , Athens, Greece , Bad Nauheim, Germany , Bangkok, Thailand , Barcelona, Spain , Beijing, China , Bergamo, Italy , Bernau, Germany and 66 more locations